Marion Wiesmann
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Cancer-related Molecular Pathways, Chronic Lymphocytic Leukemia Research, Advanced Breast Cancer Therapies, Oral and gingival health research
Most-Cited Works
- → High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response(2015)1,424 cited
- → Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor(2011)525 cited
- → Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials(2014)491 cited
- → CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors(2014)432 cited
- → Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/β-catenin signaling is activated in human colon tumors(2001)367 cited
- → The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice(2016)302 cited
- → CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma(2004)288 cited
- beta-Catenin regulates vascular endothelial growth factor expression in colon cancer.(2003)
- → Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer(2011)249 cited
- → Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib(2010)150 cited